Months after losing its hepatitis C collaboration with Janssen, Achillion is trying to cut costs.

Months after raising a $107 million series C, Arcus Biosciences has filed for a $100 million IPO.

Three years after its last misfire, Israeli biotech PolyPid is having another go at a Nasdaq listing, seeking $86 million to develop anti-infectives.

Sarepta expects to resume dosing in a U.K. trial of its DMD drug golodirsen pending MHRA approval.

ReViral has hit its primary and secondary endpoints in a small midstage trial testing its experimental med against RSV.

Solid Bio has pressed on after its plans for an IPO fell apart—with a cut-price offering for an upsized stake.

Eureka Therapeutics will advance its T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma into the clinic.

Chinese biotech Innovent Biologics is reportedly considering a $200 million IPO later this year that could take place in the U.S.